|
|
Founded in 2004, Cannasat is a clinical stage pharmaceutical company developing products to treat neurological disorders such as neuropathic pain and schizophrenia. Cannasat currently has two new drugs in its pipeline: Relivar and Modulyn. Relivar is currently in Phase I clinical trials and Modulyn is scheduled to begin Phase I trials in 2009.![]() |
|||||||||||||||||||||||||||||||||||